| Followers | 65 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Friday, March 07, 2025 9:06:21 PM
When MHRA news hits you and I and the other underwater shareholders in NWBO have a tough choice to make.
Several times we have had the chance to sell and escape this nightmare with a whole skin or even a modest profit (if we studiously ignore opportunity cost) and we failed to take advantage.
A lot of shareholders will not make the same mistake again because they know this will be their last chance.
That is precisely why Flipper, others and I are setting the standard that NWBO needs to release big news concurrently with MHRA approval.
That is why we have made it clear that management knows or should know that the current situation (including their silence) has disheartened shareholders and that if they have something for us and at the same time they give a damn about you and others and me, then they cannot pussyfoot around or be vague or coy or ambiguous. Say it plainly, say it loudly and say it simultaneously with MHRA approval and not one hour later.
Several times we have had the chance to sell and escape this nightmare with a whole skin or even a modest profit (if we studiously ignore opportunity cost) and we failed to take advantage.
A lot of shareholders will not make the same mistake again because they know this will be their last chance.
That is precisely why Flipper, others and I are setting the standard that NWBO needs to release big news concurrently with MHRA approval.
That is why we have made it clear that management knows or should know that the current situation (including their silence) has disheartened shareholders and that if they have something for us and at the same time they give a damn about you and others and me, then they cannot pussyfoot around or be vague or coy or ambiguous. Say it plainly, say it loudly and say it simultaneously with MHRA approval and not one hour later.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
